Shanghai RAAS Blood Products (002252.SZ)

Executive Summary

Shanghai RAAS Blood Products is one of China's largest vertically integrated plasma-derived biopharmaceutical companies, operating a comprehensive value chain from plasma collection through clinical-grade fractionation to commercialization of life-saving hemotherapy and immunotherapy products. As a publicly listed strategic national asset (ticker: 002252.SZ), RAAS benefits from China's protected blood products market and government self-sufficiency initiatives, which shield it from foreign competition and provide stable demand growth. The company maintains rigorous GMP compliance and advanced viral safety protocols, positioning it as a trusted supplier in a sector with high regulatory barriers. With a market cap of approximately $37 billion, RAAS is a dominant player in China's plasma industry, leveraging its extensive network of plasma collection stations and state-of-the-art fractionation facilities to capture a significant share of the growing domestic market driven by aging demographics and expanding clinical applications. RAAS's growth trajectory is supported by ongoing capacity expansions, potential new product approvals, and favorable government policies encouraging domestic blood product self-sufficiency. The company's robust R&D pipeline targets high-value immune globulins and coagulation factors, addressing unmet medical needs in immunology and hematology. Despite headwinds from regulatory tightening and pricing pressures, RAAS's entrenched market position, vertical integration, and alignment with national health security priorities underpin its long-term growth prospects. The company's ability to consistently increase plasma collection volumes and improve operational efficiency will be key drivers of margin expansion and shareholder value creation.

Upcoming Catalysts (preview)

• Q3 2026New product approval: Subcutaneous immunoglobulin (SCIG) for primary immunodeficiency75% success
• Q4 2026Capacity expansion at new plasma collection stations in inland provinces90% success
• TBDGovernment policy update on blood product self-sufficiency targets100% success